Design Controls
Structured process governing the design of medical devices.
Definition
Design controls (21 CFR 820.30) are an interrelated set of practices and procedures that are incorporated into the design and development process to manage design inputs, outputs, verification, validation, transfer, and changes. Design controls usually run through a design and development plan, design inputs (user needs turned into requirements), design outputs (drawings, specifications, software), design reviews, verification, validation, design transfer to production, and change control. Traceability between these elements is key evidence in submissions and inspections. Since the QMSR took effect on February 2, 2026, FDA enforces design controls through ISO 13485:2016 as incorporated by reference in 21 CFR Part 820, so the old section numbers are now historical. Requirements now sit in ISO 13485 clause 7.3.What this means in practice
Design controls are required for almost all Class II and Class III devices and for select Class I devices listed in 21 CFR 820.30(a)(2). They form the audit trail (design history file) used by FDA, Notified Bodies, and internal auditors to evaluate design quality. Under QMSR (effective February 2026), design controls are preserved and aligned with ISO 13485 clause 7.3. The typical elements are: design and development planning, design inputs, design outputs, design review, verification, validation, transfer, and changes, with a design history file (DHF) collecting the evidence.Examples
- A Class III implantable device team maintaining a phase-gated DHF with formal design reviews at each stage and an approved traceability matrix linking user needs to validation protocols.
- A SaMD manufacturer using an electronic QMS to link software requirements (inputs) to code modules (outputs), unit tests (verification), and clinical usability studies (validation).
- •Treating verification and validation as interchangeable. Verification confirms outputs meet inputs; validation confirms the device meets user needs in its intended environment.
- •Weak design inputs. Vague or unmeasurable inputs make verification impossible and are one of the most common Form 483 observations.
- •Skipping formal design reviews or performing them without an independent reviewer, which invalidates the review evidence under 820.30(e).
- •Poor design change control. Every post-transfer change requires evaluation, verification/validation as appropriate, and documentation before implementation.
Frequently asked questions
Cross-references
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsConfirming design outputs meet inputs (V) and that devices meet user needs (V).
Compilation of records describing the design history of a finished device.
International standard for medical device quality management systems.
FDA's harmonized successor to the QSR, incorporating ISO 13485:2016 by reference.
QMS Foundations
· From this learning pathFDA's current good manufacturing practice (cGMP) requirements for medical devices.
Process for receiving, evaluating, and responding to device complaints.
Systematic process to investigate and resolve quality issues and prevent recurrence.
Notice of inspectional observations issued at the conclusion of an FDA inspection.
Where this term appears across MedTech Terms.
- QMS FoundationsLesson 4 of 10
Sources
3 sourcesEvery citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.
- 121 CFR 820.30 Design ControlsTier 1 VerifiedeCFRecfr.gov
- 2FDA Design Control Guidance for Medical Device Manufacturers (withdrawn February 2026, archived copy linked by FDA)Tier 2 UncheckedFDAfda.gov
- 3ISO 13485 Standard PageTier 1 VerifiedISOiso.org
Inline markers like [1] jump to the matching reference above.